Loading...
Docoh

Connect Biopharma (CNTB)

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

CNTB stock data

Calendar

31 Mar 22
24 Sep 22
31 Dec 22
Quarter (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
52.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 32 29 +10.3%
Opened positions 9 8 +12.5%
Closed positions 6 11 -45.5%
Increased positions 6 11 -45.5%
Reduced positions 6 4 +50.0%
13F shares Current Prev Q Change
Total value 651.1M 124.97M +421.0%
Total shares 28.88M 31.58M -8.5%
Total puts 0 10K EXIT
Total calls 0 0
Total put/call ratio Infinity
Largest owners Shares Value Change
Ra Capital Management 6.99M $6.08M 0.0%
BioFortune 5.95M $30.64M 0.0%
Advantech Capital II 4.76M $24.53M 0.0%
Qiming Venture Partners VII 3.2M $16.47M 0.0%
Adage Capital Partners GP, L.L.C. 1.68M $1.46M +16.7%
BLK Blackrock 1.43M $1.25M -35.8%
Kynam Capital Management 739.65K $643K +224.8%
JHG Janus Henderson 720K $637K -55.0%
Ikarian Capital 677.86K $591K 0.0%
Ubs Oconnor 651.51K $567M NEW
Largest transactions Shares Bought/sold Change
FMR 184 -2.28M -100.0%
JHG Janus Henderson 720K -879.83K -55.0%
BLK Blackrock 1.43M -801.43K -35.8%
Ubs Oconnor 651.51K +651.51K NEW
Kynam Capital Management 739.65K +511.89K +224.8%
RTW Investments 0 -446.56K EXIT
Citadel Advisors 409.66K +409.66K NEW
C Citigroup 375.37K +374.31K +35547.4%
BCS Barclays 0 -313.73K EXIT
BAC Bank Of America 502 -295.63K -99.8%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
Proxies
No filings